Sutro Biopharma (STRO) Stock Price, News & Analysis

Company Overview

Sutro Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. The company uses its proprietary XpressCF cell-free protein synthesis platform to design and manufacture antibody-drug conjugates (ADCs) and immunostimulatory antibody conjugates intended to selectively target tumor cells while limiting damage to healthy tissue.

Sutro’s pipeline has included luveltamab tazevibulin, also known as luvelta or STRO-002, a folate receptor alpha-directed ADC being investigated for the treatment of ovarian and endometrial cancers. The company has also advanced additional preclinical and clinical programs directed at cancer-related targets, including therapies designed to deliver cytotoxic or immune-activating payloads to tumors.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma conducts research and development activities in the United States and works with external pharmaceutical partners on selected programs. The company’s operations are primarily focused on oncology research, drug discovery, clinical development and manufacturing-related capabilities. Sutro is led by a management team with experience in biotechnology, pharmaceutical development and oncology therapeutics.

Key Stats

• Today's Range: $15.25 to $16.13
• 50-Day Range: $15.48 to $29.73
• 52-Week Range: $7.15 to $43.85
• Volume: 348,384 shs
• Average Volume: 256,523 shs
• Market Capitalization: $256.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $47.30
• Consensus Rating: Buy

Sutro Biopharma Stock Analysis - MarketRank™

Sutro Biopharma scored higher than 67% of companies evaluated by MarketBeat, and ranked 209th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Sutro Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 10 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Sutro Biopharma has a consensus price target of $47.30, representing about 205.6% upside from its current price of $15.48.

Amount of Analyst Coverage

Sutro Biopharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Sutro Biopharma are expected to grow in the coming year, from ($8.41) to ($6.95) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sutro Biopharma is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sutro Biopharma is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.11% of the float of Sutro Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Sutro Biopharma has a short interest ratio ("days to cover") of 8.53.

Change versus previous month

Short interest in Sutro Biopharma has recently decreased by 2.49%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sutro Biopharma does not currently pay a dividend.

Dividend Growth

Sutro Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: N/A

News Sentiment

Sutro Biopharma has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Healthcare companies.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sutro Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.80% of the stock of Sutro Biopharma is held by insiders.

Percentage Held by Institutions

96.99% of the stock of Sutro Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 9/18/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:STRO
• CIK: 1382101
• Web: www.sutrobio.com
• Phone: (650) 392-8412
• Fax: N/A
• Employees: 128
• Year Founded: 2003

Price Target and Rating

• Average Price Target for Sutro Biopharma: $47.30
• High Price Target: $60.00
• Low Price Target: $27.00
• Potential Upside/Downside: +205.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($11.97)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$191.09 million
• Net Margins: -395.25%
• Pretax Margin: -395.46%
• Return on Equity: N/A
• Return on Assets: -88.12%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.32
• Quick Ratio: 3.32

Sales & Book Value

• Annual Sales: $102.48 million
• Price / Sales: 2.50
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($15.43) per share
• Price / Book: -1.00

Miscellaneous

• Outstanding Shares: 16,580,000
• Free Float: 16,283,000
• Market Cap: $256.66 million
• Optionable: Optionable
• Beta: 1.48